Research Analysts’ Recent Ratings Changes for Stoke Therapeutics (STOK)

Several analysts have recently updated their ratings and price targets for Stoke Therapeutics (NASDAQ: STOK):

• 3/21/2026 – Stoke Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/20/2026 – Stoke Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $36.00 to $60.00. They now have a “buy” rating on the stock.
• 3/19/2026 – Stoke Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $39.00 price target on the stock.
• 3/18/2026 – Stoke Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.
• 3/17/2026 – Stoke Therapeutics had its price target raised by Wedbush from $36.00 to $38.00. They now have an “outperform” rating on the stock.
• 3/17/2026 – Stoke Therapeutics had its price target raised by Needham & Company LLC from $35.00 to $40.00. They now have a “buy” rating on the stock.
• 2/23/2026 – Stoke Therapeutics is now covered by Wolfe Research. They set an “outperform” rating and a $40.00 price target on the stock.
• 2/23/2026 – Stoke Therapeutics is now covered by Wolfe Research. They set an “outperform” rating and a $40.00 price target on the stock.
• 2/5/2026 – Stoke Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $60.00 price target on the stock.
• 2/5/2026 – Stoke Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $60.00 price target on the stock.

Insider Buying and Selling

In other news, Director Adrian R. Krainer sold 33,243 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $39.74, for a total transaction of $1,321,076.82. Following the transaction, the director directly owned 283,302 shares of the company’s stock, valued at approximately $11,258,421.48. This trade represents a 10.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jason Hoitt sold 1,931 shares of Stoke Therapeutics stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $60,517.54. Following the sale, the insider owned 10,276 shares in the company, valued at approximately $322,049.84. This represents a 15.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 69,699 shares of company stock valued at $2,526,714 in the last ninety days. Insiders own 9.50% of the company’s stock.

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.